Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2 by Steef van de VeldePlatinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2 by Steef van de Velde

Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2

EditorSteef van de Velde, J.H. Schornagel

Hardcover | April 30, 1996

Pricing and Purchase Info


Earn 1,685 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


Free University, Amsterdam, The Netherlands. Proceedings from the Seventh International Symposium held March 1-4, 1995, in Amsterdam, the Netherlands. Advanced research for investigators and oncologists. 118 international contributors.
Title:Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2Format:HardcoverDimensions:368 pages, 10 × 7.01 × 0 inPublished:April 30, 1996Publisher:Springer US

The following ISBNs are associated with this title:

ISBN - 10:0306452871

ISBN - 13:9780306452871

Look for similar items by category:


Table of Contents

Synthesis and Activity of Platinum Compounds: NMR Spectroscopy of Platinum Drugs: From DNA to Body Fluids (K.J. Barnham et al.). Transdiamminedichloroplatinum (II) Is Not an Antitumor Drug: Why? (R. Dalbiès et al.). Iminoethers as Carrier Ligands: A Novel Transplatinum Complex Possessing in Vitro and in Vivo Antitumor Activity (M. Coluccia et al.). Molecular Dynamics Simulations on Cisplatin Adducts with Dinucleotides (J. Kozelka). Orally Active DACHPt (IV) Compounds (Y. Kidani et al.). Clinical Pharmacology: Pharmacokinetic-Pharmacodynamic Relationships (P. Canal, E. Chatelut). Clinical Pharmacology of Carboplatin Administered in Alternating Sequence with Paclitaxel in Patients with Nonsmall Cell Lung Cancer: A European Cancer Centre (ECC) Study (L.J.C. van Warmerdam et al.). The Clinical Development of the Oral Platinum Anticancer Agent JM216 (I. Judson et al.). Biochemistry and Molecular Pharmacology: Membrane Transportof Platinum Compounds (G. Los et al.). Detection of Adducts Formed upon Treatment of DNA with Cisplatin and Carboplatin (A.M.J. FichtingerSchepman et al.). Detection of Platinum Lesions at the Nucleotide Level in Cells Using Single Strand Ligation PCR (J.A. Hartley et al.). A Review of the Modulation ofCisplatin Toxicities by Chemoprotectants (R.T. Dorr). CombinationTherapy with Cisplatinum and EGF Receptor Blockade (J. Mendelsohnet al.). Clinical Studies: Oxaliplatin: Update on an Activeand Safe Dach Platinum Complex (P. Soulié et al.). Combination of Different Platinum Compounds: Issues, Strategies and Experience (F.M. Muggia). Phase I and II Studies with Lobaplatin (H. Fiebig). Phase I Trials of Ormaplatin (NSC 363812)(M.C. Christian). 254S, NK121 and TRK710 (M. Ogawa). Clinical Trials of Oxaliplatin and DWA2114R (T. Taguchi). Incorporating Assessments of Sequencedependence in Developmental Studies of Combination Chemotherapy Regimens Containing New Agents and Platinum Compounds (E.K. Rowinsky). Review of Carboplatinbased Highdose Chemotherapy Combinations in the Autotransplant Setting(S. Rodenhuis et al.). Treatment Intensification in Germcell Tumors (J.P. Droz et al.). Nonplatinum Metal Complexes: Overview of Tumorinhibiting Nonplatinum Complexes (B.K. Keppler, E.A. Vogel). Phenotypic Aspects of Platinum Resistance (T. Fojo et al.). How Does Platinum Kill the Cell? The Cisplatininduced Cellular Injury Response (S.B. Howell et al.). Controversy Session: Cisplatin vs. Carboplatin? Carboplatinvs. Cisplatin in the Chemotherapy of Solid Tumors: Procarboplatin (D.S. Alberts). Cisplatin and Carboplatin in Testis and Ovarian Cancer: Procisplatin (S.D. Williams). Resistance: Hypersensitivity to Cisplatin in Mouse LeukemiaL1210/0 Cells: An XPG DNA Repair Defect (R. Wood et al.). 4 additional articles. Index.